HepaRegeniX Closes €21.5M in Funding

(SeaPRwire) – Tübingen, Germany, April 15, 2025 – (“HepaRegeniX”), a clinical-stage company dedicated to advancing novel therapies for the treatment of acute and chronic liver diseases, today announced the completion of its second round of financing totaling €21.5 million and welcomed Wellington Partners to its investor group. HepaRegeniX plans to use the proceeds from the financing to complete the ongoing Phase Ib trial and advance HRX-215, the…

HepaRegeniX Closes €21.5M in Funding

HepaRegeniX GmbH, a Tuebingen, Germany-based clinical-stage company advancing novel therapies to treat acute and chronic liver diseases, raised €21.5M in funding. Backers included Wellington Partners. The company intends to use the funds to complete its ongoing Phase Ib trial and to advance the Phase IIa clinical trial for HRX-215, its lead clinical candidate in liver regeneration. Led […] The post HepaRegeniX Closes €21.5M in Funding appeared f…

Pegbelfermin Shows Promise in Addressing Liver Fibrosis in MASH

Data from patients across 3 different randomized controlled trials showed improvements in both adiponectin and PRO-C3, primary end points in the trials.